ArticleJournal of general internal medicine2023
Envisioning Minimally Disruptive Opioid Use Disorder Care.
Article in Journal of general internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.Substance abuse treatment, prevention, and policy · 2023Pooled it
- Addiction Consult Services, Mortality, and Acute Care Utilization in Inpatients With Opioid Use Disorder: A Secondary Analysis of a Cluster Randomized Clinical Trial.JAMA network open · 2025Trial
- Review
- Factors influencing family physicians' willingness to prescribe opioid agonist therapy using virtual modalities: a qualitative analysis.Frontiers in medicine · 2026Article
- Population-Level Health Benefits and Harms Associated With Buprenorphine/Naloxone vs Methadone.JAMA network open · 2025Article
- Perspectives on prescribed safer supply programs among people who inject drugs in Baltimore, Maryland: A mixed methods study among individuals highly affected by drug toxicity.The International journal on drug policy · 2025Article
- Hospital Provider's Perspectives on MOUD Initiation and Continuation After Inpatient Discharge.Journal of general internal medicine · 2025Article
- Correlates of recovery capital among women in jails: Leveraging a dimensional recovery framework.Addiction research & theory · 2025Article
- Lessons from the National institutes of health innovation corps program: defining barriers to developing and commercializing novel solutions for persons with opioid use disorder.Addiction science & clinical practice · 2025Article
- "I still can feel the sickness": Withdrawal experiences of people on methadone maintenance treatment.Journal of substance use and addiction treatment · 2025Article
- Bridging the Gap Between Knowledge and Practices Pertaining to Naloxone Use: A Single-Institution Experience in North Carolina.Journal of patient-centered research and reviews · 2025Article
- How Racialized Approaches to Opioid Use Disorder and Opioid Misuse Management Hamper Pharmacoequity for Cancer Pain.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Patient experiences of buprenorphine dispensing from a mobile medical unit.Addiction science & clinical practice · 2024Article
- Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.Harm reduction journal · 2024Article
- Barriers to opioid use disorder treatment among people who use drugs in the rural United States: A qualitative, multi-site study.Social science & medicine (1982) · 2024Article
- Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities.Harm reduction journal · 2023Article
- Treatment setting among individuals with opioid use and criminal legal involvement, housing instability, or Medicaid insurance, 2015-2021.Drug and alcohol dependence reports · 2023Article
- Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder.JAMA health forum · 2023Observational
- "Come try it out. Get your foot in the door:" Exploring patient perspectives on low-barrier treatment for opioid use disorder.Drug and alcohol dependence · 2023Article
- History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.Drug and alcohol dependence reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Most people who need and want treatment for opioid addiction cannot access it. Among those who do get treatment, only a fraction receive evidence-based, life-saving medications for opioid use disorder (MOUD). MOUD access is not simply a matter of needing more clinicians or expanding existing treatment capacity. Instead, many facets of our health systems and policies create unwarranted, inflexible, and punitive practices that create life-threatening barriers to care. In the USA, opioid use disorder care is maximally disruptive. Minimally disruptive medicine (MDM) is a framework that focuses on achieving patient goals while imposing the smallest possible burden on patients' lives. Using MDM framing, we highlight how current medical practices and policies worsen the burden of treatment and illness, compound life demands, and strain resources. We then offer suggestions for programmatic and policy changes that would reduce disruption to the lives of those seeking care, improve health care quality and delivery, begin to address disparities and inequities, and save lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.